Mycobacterial Infection after Intravesical Bacillus Calmette-Guërin Treatment for Bladder Cancer: A Case Report
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Bacillus Calmette-Guërin (BCG) has been traditionally used as a vaccine against tuberculosis. Further, intravesical administration of BCG has been shown to be effective in treating bladder cancer. Although BCG contains a live attenuated strain of Mycobacterium bovis, complications such as M. bovis BCG infection caused by BCG administration are extremely rare. Here, we report a case of BCG infection occurring after intravesical BCG therapy. A 67-yr-old man presented with azotemia and weight loss. He had been diagnosed with bladder cancer 4 yr back, and had undergone transurethral resection of the bladder tumor and intravesical BCG (Tice strain) therapy at that time. An acid-fast bacterial strain was isolated from his urine sample. We did not detect Mycobacterium tuberculosis protein 64 (MPT-64) antigen in the isolates obtained from his sample, and multiplex PCR and PCR-reverse blot hybridization assay indicated that the isolate was a member of the M. tuberculosis complex, but was not M. tuberculosis. Finally, sequence analysis of 16S ribosomal RNA and DNA gyrase, subunit B (gyrB) suggested that the organism was M. bovis or M. bovis BCG. Although we could not confirm that M. bovis BCG was the causative agent, the results of the 3 molecular methods and the MPT-64 antigen assay suggest this finding. This is an important finding, especially because M. bovis BCG cannot be identified using common commercial molecular genetics tools.
Abstract
Bacillus Calmette-Guërin (BCG) has been traditionally used as a vaccine against tuberculosis. Further, intravesical administration of BCG has been shown to be effective in treating bladder cancer. Although BCG contains a live attenuated strain of Mycobacterium bovis, complications such as M. bovis BCG infection caused by BCG administration are extremely rare. Here, we report a case of BCG infection occurring after intravesical BCG therapy. A 67-yr-old man presented with azotemia and weight loss. He had been diagnosed with bladder cancer 4 yr back, and had undergone transurethral resection of the bladder tumor and intravesical BCG (Tice strain) therapy at that time. An acid-fast bacterial strain was isolated from his urine sample. We did not detect Mycobacterium tuberculosis protein 64 (MPT-64) antigen in the isolates obtained from his sample, and multiplex PCR and PCR-reverse blot hybridization assay indicated that the isolate was a member of the M. tuberculosis complex, but was not M. tuberculosis. Finally, sequence analysis of 16S ribosomal RNA and DNA gyrase, subunit B (gyrB) suggested that the organism was M. bovis or M. bovis BCG. Although we could not confirm that M. bovis BCG was the causative agent, the results of the 3 molecular methods and the MPT-64 antigen assay suggest this finding. This is an important finding, especially because M. bovis BCG cannot be identified using common commercial molecular genetics tools.
참고문헌 (17)
- Bellmunt J, "Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 21(5), pp.134~136 (2010)
- Lamm DL, "Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bla-dder cancer", J Urol, 147, pp.596~600 (1992)
- Harving SS, "Granulomatous epididymo-orchitis, a rare complication of intravesical bacillus Calmette-Guérin therapy for urothelial cancer", Scand J Urol Nephrol, 43, pp.331~333 (2009)
- Ilgan S, "Incidental detection of granulomatous prostatitis by F-18 FDG PET", CT in a patient with bladder cancer: a rare complication of BCG instillation therapy, 2009, pp.34, 613~614
- Korac M, "Disseminated BCG infection in patients with urinary bladder carcinoma", Med Pregl, 62, pp.592~595 (2009)
- CLSI, "Interpretive criteria for identification of bacteria and fungi by DNA target sequencing; approved guideline. CLSI document MM18-A" (2008), Clinical and Laboratory Standards Institute
- Nakajima C, "Identification of mycobacterium tuberculosis clinical isolates in Bangladesh by a species distinguishable multiplex PCR", BMC Infect Dis, 10, pp.118~ (2010)
- 남상복, "표재성 방광종양에서 BCG 주입요법 후 요관 주위에 발생한 결핵성 육아종에 의한 요관폐쇄", Korean Journal of Urology, 47(4), pp.436~439 (2006), 대한비뇨기과학회
- 전형진, "방광종양에서 방광 내 BCG주입 후 신에 발생한 결핵성 육아종", Korean Journal of Urology, 43(12), pp.1104~1106 (2002), 대한비뇨기과학회
- 나동집, "Two cases of pulmonary complications following intravesical bacillus Calmette-Guerin immunotherapy in patients with superficial bladder cancer", Tuberculosis and Respiratory Diseases, 46(6), pp.869~878 (1999), Korean National Tuberculosis Association
- 김상훈, "Tuberculous Prostatic Abscess Following Intravesical Bacillus Calmette-Guérin Instillation", Korean Journal of Urology, 50(2), pp.186~187 (2009), 대한비뇨기과학회
- Son JI, "A case of granulomatous hepatitis developed after intravesical BCG instillation for bladder cancer", Korean J Gastroenterol, 39, pp.375~378 (2002)
- Kim SH, "BCG osteomyelitis caused by the BCG Tokyo strain and confirmed by molecular method", Vaccine, 26, pp.4379~4381 (2008)
- Nagai S, "Isolation and partial characterization of major protein antigens in the culture fluid of mycobacterium tuberculosis", Infect Immun, 59, pp.372~382 (1991)
- Harboe M, "Properties of proteins MPB64, MPB70, and MPB80 of mycobacterium bovis BCG", Infect Immun, 52, pp.293~302 (1986)
- Li H, "Evidence for absence of the MPB64 gene in some substrains of mycobacterium bovis BCG", Infect Immun, 61, pp.1730~1734 (1993)
- Behr MA, "A historical and molecular phylogeny of BCG strains", Vaccine, 17, pp.915~922 (1999)